Meta AnalysisID 6799
脑栓通胶囊治疗缺血性脑卒中的系统评价与Meta分析
CRD42023482981
To determine the efficacy and safety of Naoshuantong capsule in the treatment of ischemic stroke (IS).
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6799
- Evidence Id
- 15357
- Core Evidence Id
- 15357
- Source Meta Analysis Id
- 6782
- Herb2 Meta Analysis Id
- HBMA006782
- Crd Id
- CRD42023482981
- Title
- Naoshuantong capsule for ischemic stroke:A Systematic Review and Meta-Analysis
- Review Question
- To determine the efficacy and safety of Naoshuantong capsule in the treatment of ischemic stroke (IS).
- Study Type Included
- Randomized controlled trials.
- Condition Being Studied
- Stroke is the second leading cause of death and the third leading cause of death and disability worldwide, with 12.2 million stroke events and 6.55 million deaths in 2019, with ischemic stroke being the most common type of stroke globally. Naoshuantong capsule is a compound prescription formulated according to the meridian theory of traditional Chinese medicine (TCM) and is approved by the State Food and Drug Administration of China for the treatment of ischemic stroke. However, the safety of Naoshuantong capsule in improving neurological function, activities of daily living, clinical efficacy and complications during treatment in patients with ischemic stroke are still controversial.
- Participant
- Adult patients with ischemic stroke as diagnosed by guidelines.
- Animal
- Human Disease Modelled
- Intervention
- Naoshuantong capsule.
- Comparator Control
- Placebo or no intervention. Routine treatment or co-interventions will also be allowed when the routine treatment or co-interventions are administered equally to all intervention groups of a trial.
- Main Outcome
- Improvement of neurological impairment in acute phase assessed by National Institute of Health Stroke Scale (NIHSS).
- Outcome Measure
- Additional Outcome
- 1. Activity of daily living measured with Barthel Index (BI), modified Rankin Scale(mRS) and other related scales. 2. Recurrence rate of cerebrovascular events. 3. Quality of life assessed by EuroQol Five Dimensions Questionnaire (EQ-5D), Quality of life scale for stroke (SS-QOL) and other related scales. 4. Safety outcome assessments included adverse reactions (nausea, vomiting, diarrhea, etc.) and adverse events (death, major bleeding, functional disability etc.).
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- MeSH headings have not been applied to this record
- Contact
- Cuilin Que [email protected]
- Organisational Affiliation
- Dongzhimen Hospital, Beijing University of Chinese Medicine;Beijing University of Chinese Medicine
- Funding Source
- 1.Supported by the 2019 Major Difficult Diseases Clinical Collaboration Capacity Building Project of Traditional Chinese and Western Medicine-cerebral Infarction 2.Construction project of cerebral vascular disease prevention and treatment office of traditional Chinese medicine in Beijing
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-11-14
- Registration Date
- 2023-11-26
- Anticipated Start Date
- 2023-11-06
- Anticipated Completion Date
- 2024-03-31
- Title Cn
- 脑栓通胶囊治疗缺血性脑卒中的系统评价与Meta分析
- Title En
- Naoshuantong capsule for ischemic stroke:A Systematic Review and Meta-Analysis
- Bilingual Status
- complete